Then they did this study:
http://www.wjgnet.com/1007-9327/13/5317.pdf
METHODS: One hundred chronic HCV infection
patients failed in interferon treatment were enrolled and
randomly assigned to receive combined intravenous and
oral antioxidants or placebo, or oral treatment alone.
Primary end points were liver enzymes, HCV-RNA levels
and histology.
RESULTS: Combined oral and intravenous antioxidant
therapy was associated with a significant decline in
ALT levels in 52% of patients who received antioxidant
therapy vs 20% of patients who received placebo (P =
0.05). Histology activity index (HAI) score at the end of
treatment was reduced in 48% of patients who received
antioxidant therapy vs 26% of patients who received
placebo (P = 0.21). HCV-RNA levels decreased by 1-log
or more in 28% of patients who received antioxidant
therapy vs 12% who received placebo (P = NS). In part
Ⅱ of the trial, oral administration of antioxidants was not
associated with significant alterations in any of the end
points.
CONCLUSION: Antioxidant therapy has a mild beneficial
effect on the inflammatory response of chronic HCV
infection patients who are non-responders to interferon.
Combined antiviral and antioxidant
The aim of the present trial was to determine the effect of a mixture of antioxidants
on the inflammatory response of chronic HCV infection patients who were
non-responders to interferon, in a double blind placebo controlled trial. Two
different treatment regimens were studied and compared. The data suggest
that the combined use of intravenous and oral antioxidants mildly alleviates the
inflammatory response in these patients.